Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes

References

• Greenberg P, Cox C, Lebeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood89, 2079–2088 (1997).
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J. Clin. Oncol.25(23), 3503–3510 (2007).
   PubMed Web of Science ®Google Scholar
• Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med.134(7), 573–586 (2001).
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer123(1), 8–13 (2008).
   PubMed Web of Science ®Google Scholar
• Marcucci G, Silverman L, Eller M, Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J. Clin. Pharmacol.45(5), 597–602 (2005).
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell A, Abraham S et al. FDA approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res.11(10), 3604–3608 (2005).
   PubMed Web of Science ®Google Scholar
• Kaminskas E, Farrell AT, Wang YC et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist10(3), 176–182 (2005).
   PubMed Web of Science ®Google Scholar
• Silverman LR, Holland JF, Demakos EP et al. 5-azacyidine in myelodysplastic syndromes the experience at Mount Sinai Hospital, New York. Leuk. Res.1, 21–29 (1994).
   Google Scholar
• Silverman LR, Demakos EP, Peterson BL, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol.20(10), 2429–2440 (2002).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood108(2), 419–425 (2006).
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL et al.; Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol.24(24), 3895–3903 (2006).
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti G, Hellström-Lindberg E et al. Azacitidine (AZA) prolongs overall survival (OS) in higher risk MDS patients compared with conventional care regimens (CCR). Results of the AZA-001 Phase III Study. Lancet Oncol. (2009) (In press).
   PubMedGoogle Scholar
• List A, Fenaux P, Mufti G et al. Effect of azacitidine (AZA) on overall survival in higher risk myelodysplastic syndromes without complete remission. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 7006).
   PubMedGoogle Scholar
• Mufti GJ, Garcia Manero G, Horvath N et al. Prolonged survival in higher risk myelodysplastic syndromes patients with -7/del7q treated with azacitidine. Haematologica93(Suppl. 1), 369 (2008) (Abstract 0928).
   Google Scholar
• Silverman LR, Fenaux P, Mufti GJ, The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (pts) with myelodysplastic syndromes (MDS). ASH Annual Meeting Abstracts. Blood112, 227 (2008).
   Web of Science ®Google Scholar
• Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist6(Suppl. 5), 8–14 (2001).
   PubMed Web of Science ®Google Scholar
• Gore SD, Baylin S, Sugar E et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res.66, 6361–6369 (2006).
   PubMed Web of Science ®Google Scholar
• Rudek MA, Zhao M, He P et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J. Clin. Oncol.23(17), 3906–3911 (2005).
   PubMed Web of Science ®Google Scholar
• Soriano AO, Yang H, Faderl S et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood110, 2302–2308 (2007).
   PubMed Web of Science ®Google Scholar
• Voso MT, Santini V, Finelli C et al. 5-azacytidine, valproic acid and all trans retinoic acid in INT-2/high risk myelodysplastic syndromes, first results of the GIMEMA MDS0205 multicenter trial. Haematologica93(Suppl. 2), S77 (2008) (Abstract 092).
   Google Scholar
• Kuendgen A, Bug G, Ottmann O et al. Treatment of poor risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Blood112, (2008) (Abstract 3639).
   Google Scholar
• Raffoux E, de Labarthe A, Cras A et al. Epigenetic therapy with 5-azacitidine, valproic acid, and ATRA in patients with high-risk AML or MDS: results of the French VIVEDEP Phase II Study. ASH Annual Meeting Abstracts. Blood112, 763 (2008).
   Web of Science ®Google Scholar
• Craddock C, Goardon N, Griffiths M et al. 5’ azacitidine in combination with valproic acid induces complete remissions in patients with advanced acute myeloid leukaemia but does not eradicate clonal leukaemic stem/progenitor cells. ASH Annual Meeting Abstracts. Blood112, 945 (2008).
   Google Scholar
• Silverman LR, Verma A, Odchimar-Reissig R et al. A Phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium. ASH Annual Meeting Abstracts. Blood112, 3656 (2008).
   Web of Science ®Google Scholar
• Martin MG, Walgren R, Procknow E et al. Azacitidine-induced changes in the MDS methylome are associated with clinical responses. ASH Annual Meeting Abstracts. Blood112, 2691 (2008).
   Google Scholar
• Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Azacitidine prolongs overall survival (OS) and reduces infections and hospitalizations in patients (pts) with WHO-defined acute myeloid leukemia (AML) compared with conventional care regimens (CCR). ASH Annual Meeting Abstracts. Blood112, 3636 (2008).
   Google Scholar
• Maurillo L, Spagnoli A, Genuardi M et al. 5-azacytidine for the treatment of acute myeloid leukemia: a retrospective, multicenter study of 55 patients. ASH Annual Meeting Abstracts. Blood112, 1947 (2008).
   Google Scholar
• Grövdal M, Khan R, Aggerholm A et al. Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS–AML) in complete remission (CR) after induction chemotherapy. ASH Annual Meeting Abstracts. Blood112, 223 (2008).
   Web of Science ®Google Scholar
• Santini V, Fenaux P, Mufti GJ et al. Management and supportive care measures of adverse events (AEs) in higher-risk MDS patients (pts) treated with azacitidine (AZA). ASH Annual Meeting Abstracts. Blood112, 1653 (2008).
   Google Scholar
• Lyons RM, Cosgriff T, Modi S et al. Results of the initial treatment phase of a study of three alternative dosing schedules of azacitidine (Vidaza) in patients with myelodysplastic syndromes. Blood110, (2007) (Abstract 819).
   Google Scholar
• Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat. Clin. Pract. Oncol.2(Suppl. 1), S12–S23 (2005).
   Google Scholar
• Musto P, Maurillo L, Spagnoli A et al. 5-azacytidine for the treatment of low/int-1 IPSS risk myelodysplastic syndromes: results in 63 patients from the Italian patient named program. Haematologica93(Suppl. 1), 368 (2008) (Abstract 0925).
   Google Scholar
• Cheson BD, Bennett JM, Kantarjian H et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood96(12), 3671–3674 (2000).
   PubMed Web of Science ®Google Scholar